Clinical Trials Logo

Anogenital Warts clinical trials

View clinical trials related to Anogenital Warts.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT05156541 Completed - Clinical trials for Human Papillomavirus Infection

Study of the Efficacy and Safety of the Drug Ingaron (Interferon-gamma) in the Treatment of Anogenital Warts

ING-HPV-1
Start date: May 18, 2009
Phase: Phase 3
Study type: Interventional

The primary purpose of this study is to evaluate the effectiveness of destructive therapy for anogenital warts in combination with the use of Ingaron in comparison with destructive therapy.

NCT ID: NCT02377999 Completed - Anogenital Warts Clinical Trials

Safety and Efficacy of Repeat Use of Picato® 0.05% in the Treatment of Anogenital Warts

Start date: February 2015
Phase: Phase 2
Study type: Interventional

An exploratory open label, single treatment trial of anogenital warts with Picato® repeated up to 2 times with two weeks intervals.

NCT ID: NCT02276521 Completed - Cervical Cancer Clinical Trials

Evaluation of Long Term Immunity Following HPV Vaccination

Start date: February 2015
Phase: Phase 2/Phase 3
Study type: Observational

In Fiji, cervical cancer is the second most frequent cancer and the highest cause of cancer mortality in women. In 2008/9, the Ministry of Health in Fiji accepted a donation of 110,000 doses of quadrivalent HPV vaccine, Gardasil® based on the high cervical cancer disease burden. There was enough vaccine to vaccinate all girls aged 9-12 years (30,338 girls) with a three-dose schedule, but not all girls received three doses of the vaccine. This means those girls that received reduced doses may not be fully protected against the HPV genotypes present in the Gardasil®. While HPV vaccines are highly immunogenic and efficacious in the licensed three-dose schedule, there is limited information about the effectiveness of reduced dose schedules in terms of immunogenicity and memory. There is growing evidence from other studies that two doses of HPV vaccine may be sufficient for protection. Reduced schedules would be of benefit in Fiji due to improved costs and logistics. This study will examine whether one or two doses of HPV vaccine provide similar immunological evidence of long-term protection to the standard three-dose schedule in terms of antibody titres to the genotypes present in the Gardasil®. To compare immunological memory responses between dosage groups, a dose of Cervarix ® will be administered to all girls so that the magnitude of the memory responses can be measured.

NCT ID: NCT02015260 Completed - Clinical trials for Condylomata Acuminata

A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts

Start date: September 2001
Phase: Phase 2
Study type: Interventional

Objective To assess the efficacy of the topical application of Nitric Oxide, delivered using acidified nitrite. Design Multicentre, randomized, controlled, dose ranging trial. A control arm and three doses of acidified nitrite applied topically for 12 weeks with a further 12 weeks of follow up. Setting The trial setting was in European genitourinary medicine clinics Participants Male and female volunteers over 18 years of age with between 2 and 50 ano-genital warts, 328 were screened for eligibility and 299 subjects from 40 centres were randomised. Exclusions Pregnancy; concomitant Sexually Transmitted Disease; internal warts requiring treatment other than surgery /laser; diabetes ; Human Immunodeficiency Virus-positive, immunosuppressed and/or using immunosuppressive therapies; drug abuse. interventions compared - Control Placebo nitrite cream and placebo citric acid cream twice daily - A) 3% sodium nitrite + 4.5% citric acid creams twice daily - B) 6% sodium nitrite + 9% citric acid creams once daily - C) 6% sodium nitrite + 9% citric acid creams twice daily Outcomes - Primary proportion of patients with complete clearance of target warts Secondary - Time to clearance - Wart area - Wart count - Patient and investigator assessment of efficacy - Safety - Tolerability - Adherence

NCT ID: NCT01532102 Completed - Clinical trials for Human Papillomavirus Infection

Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts

Start date: February 28, 2012
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability and efficacy of the topical application of AP611074 5% gel during 6 weeks on ano-genital warts caused by human papillomavirus (HPV).

NCT ID: NCT01490008 Completed - Anogenital Warts Clinical Trials

Systemic Exposure of Catechins From Veregen 15% Ointment in Patients With External Anogenital Warts and From Oral Intake of Green Tea Beverage in Healthy Volunteers

Start date: December 2011
Phase: Phase 1
Study type: Interventional

Investigation of systemic catechin exposure following topically administered Veregen® 15% ointment in patients with external genital and perianal warts and following oral intake of a standardized green tea beverage in healthy subjects. Pharmacokinetic parameters for the main catechin EGCg used as a marker of overall catechin exposure following dermal administration in the patient group will only be calculated if sufficiently consistent data can be obtained e.g. sufficient plasma catechin concentrations to pharmacokinetically evaluate plasma profiles for plasma catechin concentrations. If applicable, a safety margin for ointment use might need to be established with respect to intolerable systemic exposures of catechins following application of Veregen® ointment. In treatment arm 1, patients with anogenital warts will apply Veregen® 15% ointment 250 mg three times daily: in the morning, at midday, and in the evening on the defined anogenital administration area (total dose of 750 mg/d) for one week . In treatment arm 2, healthy subjects will ingest 500 mL commercially available green tea beverage ("Lipton® Green Limone" distributed by PepsiCo Deutschland GmbH, Neu-Isenburg, Germany), three times daily in the morning, at midday, and in the evening (total dose of 1500 mL/d) for one week. Plasma samples will be collected to aim for a complete pharmacokinetic assessment (over 24 hours) on Days 1 and 2 at Visit 2 and on Days 7 and 8 at Visit 3 (one week after first dosing). To avoid any influence on overall systemic catechin exposure deriving from any other source than Veregen® or Lipton Green Tea, all subjects participating in the trial (patients and healthy volunteers) will be asked to follow a defined diet abstaining from food or beverages known to containing catechins (a list of all prohibited and allowed foods and beverages will be provided to all subjects). For concomitant medication, only paracetamol and oral contraceptives are allowed.

NCT ID: NCT01387412 Completed - HIV Clinical Trials

The Role of Genital Warts in HIV Acquisition in Peru

VIVA
Start date: April 2012
Phase: N/A
Study type: Observational

The primary objective of this study is to determine the role of genital warts (GW) on Human Immunodeficiency Virus (HIV) acquisition among men who have sex with men (MSM) in Peru. The secondary objectives are to determine Human Papillomavirus (HPV) prevalence in HIV positive MSM in Peru, risk factors associated with GW, and the knowledge of HPV and HIV among MSM.